MEMORIA CIENTÍFICA

INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA



IBSAL
Instituto de Investigación
Biomédica de Salamanca

El IBSAL es un instituto de investigación sanitaria acreditado por el Instituto de Salud Carlos III.
Orden de 17 de febrero de 2014 de la Secretaría de Estado de Investigación, Desarrollo e Innovación.

© del texto e imágenes: Instituto de Investigación Biomédica de Salamanca
© de la edición: Instituto de Investigación Biomédica de Salamanca

Paseo San Vicente 58-182
37007 - Salamanca

Maquetación y diseño gráfico: La Casa Torcida (www.lacasatorcida.com)

Primera edición: Junio de 2026

Todos los derechos están reservados. Queda prohibida la reproducción total o parcial de este libro por cualquier medio o procedimiento, comprendidos la reprografía y el tratamiento informático, la fotocopia o la grabación sin el permiso expreso de los titulares del copyright, así como su venta total o parcial.

MEMORIA CIENTÍFICA **IBSAL** 2025



Dibujo a bolígrafo realizado por Candelas Casas Sánchez durante la actividad "La carrera investigadora siendo mujer".


ORNADA
Palacio de Con
e junio de 20

INTRODUCTION

BIOMEDICAL RESEARCH INSTITUTE OF SALAMANCA

This Scientific Report provides a summary of the activities of the Biomedical Research Institute of Salamanca (IBSAL) during 2025, a year marked by significant changes regarding the management structure of the institute and intense research and innovation activity.

As you know, last year the re-accreditation of the Institute was achieved, conditional upon changes in the management structure. In order to respond to this requirement, the Governing Council on February 27, 2025, agreed that the Biomedical Research Foundation of Salamanca (FIBSAL) would become the new management structure of IBSAL, an event approved by the board of trustees of the aforementioned foundation. From that date, a series of administrative procedures were carried out at various levels for the transfer of material and human resources from the ICSCYL foundation to FIBSAL, which was completed in August 2025. FIBSAL commenced independent operations on September 1, 2025, as communicated through various channels to all personnel involved in the process. Finally, we are finalizing the renewal of the IBSAL founding agreement, incorporating the changes introduced with the participation of the three involved entities: Regional Ministry of Health / Regional Health Management of CYL (SACYL), University of Salamanca (USAL), and the Spanish National Research Council (CSIC). We expect this new situation, in addition to fulfilling accreditation requirements, to drive exponential growth for IBSAL.

This year, the new IBSAL website was launched with a modern and functional structure. Alongside general website information, we now feature the research portal, providing real-time updated information on human resources, projects, clinical trials, publications, and innovation, for the institute as a whole as well as for specific areas, groups, and individual researchers. We hope this information proves useful and serves as a showcase to disseminate our scientific achievements to institutions, researchers, and society at large.

In 2025, the Institute comprises 1,582 researchers, including 155 technical staff members, organized into 88 groups within IBSAL's 6 scientific areas. Likewise, 17 people make up the technical management unit that provides essential support for operations. This year we implemented new classification criteria for research groups following ISCIII guidelines, evaluating all groups with a category change in 15% of them based on CCE recommendations: 49 consolidated (56%), 15 emerging (17%), and 24 clinical associates (27%). To strengthen the activity of scientific areas, specific operational objectives were established for each area, and we decentralized internal grant funds so each area can allocate them to their specific priority needs.

The collective effort materialized in 742 scientific publications (articles and reviews), of which 457 belong to the first quartile (Q1) and 234 to the first decile (D1), the launch of 102 new competitive international, national, or regional projects (maintaining 283 active), and the initiation of 119 clinical studies (clinical trials and observational studies, maintaining 629 active), along with the addition of 38 new human resource hires. Furthermore, IBSAL researchers maintain 60 active industrial property registrations (patents and utility models) and 29 intellectual property registrations. Total funds raised reached €15,460,123.66 across competitive and institutional grants, clinical trials, R&D&I contracts, service provision, and private sector contributions, maintaining an upward trend from previous years with a distribution of 47.60% public and 52.40% private income.

The Institute held its IV IBSAL Scientific Conference on June 10, 2025, at the Conference and Exhibition Center of Castile and León, attended by over 300 researchers. Additionally, IBSAL co-organized with the three ISCIII Platforms (Biomodels & Biobanks, ITEMAS, SCREN) the 3rd Conference of ISCIII Support Platforms for Biomedical R&D&I on October 27–29, 2025, drawing over 500 nationwide researchers. The Scientific Research Support Unit has consolidated its position as a key tool for researchers, achieving success rates in the 2025 Strategic Health Action (AES) of 57% for project grants (PI) and 50% for human resources. Three new platforms were added: Biomarkers, Cardiac Imaging, and Viral Vector Production & Molecular Cloning (Viral Forge IBSAL), alongside the transformation of ITSAL into an Innovation and Medical Device Platform, totaling 12 operational platforms in 2025.

DR. LUIS GARCÍA ORTIZ — SCIENTIFIC DIRECTOR OF IBSAL

TABLE OF CONTENTS (PART 1)

1	Presentation	7
2	Context and Objectives of IBSAL	13
	2.1 Mission	14
	2.2 Vision	14
	2.3 Strategic Objectives	14
	2.4 Location	14
3	Structure and Organization	21
	3.1 Governing Bodies	22
	3.2 Scientific Direction of IBSAL	22
	3.3 Advisory Bodies	23
	3.4 Biomedical Research Foundation of Salamanca (FIBSAL)	23
	3.5 Commissions and Committees	23
	3.6 Scientific Areas and Research Groups	26
	3.7 Platforms and Infrastructures	28
	3.8 Research Structures in which IBSAL Participates	29
4	Human Resources	33
	4.1 Research Personnel	35
	4.2 Researchers in Charge of Projects	36
	4.3 Technical Staff	36
	4.4 Management Staff	37
5	Training	39
	5.1 IBSAL Training Plan	39
	5.2 Research Stays	40
	5.3 Doctoral Theses	41
6	Financial Data	43
	6.1 Revenue	43
	6.2 Indirect Costs Dedicated to HR Support Actions	45
	6.3 Balance Sheet	46
7	Research Activity	53
	7.1 Projects	53
	7.2 Clinical Studies	53
	7.3 HR Grant Calls	54
	7.4 Publications	54

TABLE OF CONTENTS (PART 2)

8	**Innovation**	**57**
	8.1 Industrial and Intellectual Property	**57**
	8.2 Clinical Practice Guidelines and Institutional Documents	**57**
9	**Communication and Outreach**	**61**
	9.1 IBSAL Press Coverage	**61**
	9.2 Social Media	**61**
	9.3 Highlighted IBSAL Activities	**63**
10	**Responsible Research and Innovation (RRI)**	**67**
	10.1 Activities with Citizens	**67**
	10.2 Activities with Citizen Associations	**67**
	10.3 Gender Equality in Science	**69**
11	**2025 Internal Grant Call**	**71**
12	**Scientific Production by Scientific Areas and Groups**	**73**

SCIENTIFIC PRODUCTION BY AREAS AND GROUPS (PART 1)

APSF	**Primary Care, Public Health and Pharmacology Area**	**74**
APSF-02	Experimental and Clinical Pharmacokinetics	**82**
APSF-03	Lifestyles and Vascular Risk	**90**
APSF-04	Aging and Dependency Prevention	**102**
APSF-05	Design and Synthesis of Bioactive Molecules (DOMOBIO)	**112**
APSF-06	Bioinformatics and Intelligent Systems	**120**
APSF-09	Cardiovascular Health Promotion	**130**
APSF-13	Bone Regeneration in Oral Surgery	**140**
APSF-15	Anesthesiology, Perioperative Medicine and Pain Research Group	**146**
APSF-16	Otorhinolaryngology	**154**
APSF-17	Disability (PCD) and Dependency I+DIS+D	**160**
APSF-18	Physiotherapy, Functional Recovery and Therapeutic Exercise	**166**
APSF-19	Neurorehabilitation	**176**
APSF-20	Obstetric-Gynecological Nursing Care	**186**
APSF-21	Vaccine Research Group	**192**
APSF-22	Rehabilitation Research	**200**
APSF-23	Innovation in Nursing and Health Care	**206**
CANC	**Cancer Area**	**214**
CANC-01	Study on Predisposition and Treatment of Solid Tumors	**222**
CANC-03	Multiple Myeloma and Novel Drugs	**244**
CANC-04	Molecular Genetics in Oncohematology	**256**
CANC-05	Molecular and Cellular Biology of Hematologic Malignancies	**272**
CANC-08	Multidisciplinary Urological and Renal Research Group	**284**
CANC-09	Tumor Genetics (GRUMUR)	**294**
CANC-10	Redox Signaling in Hematologic Neoplasms	**300**
CANC-11	Cytomics	**306**

SCIENTIFIC PRODUCTION BY AREAS AND GROUPS (PART 2)

CANC-13	Genetic Determinants in Cancer Predisposition and Treatment Response	**318**
CANC-14	Bioinformatics and Functional Genomics	**324**
CANC-15	Stem Cells, Cancer Stem Cells, and Cancer Biology	**332**
CANC-16	Signaling and Cancer	**340**
CANC-17	Drugs and Microenvironment in Multiple Myeloma	**344**
CANC-19	Cell Cycle and Cancer	**354**
CANC-22	Radiation Oncology	**358**
CANC-24	Molecular and Cellular Oncology Laboratory	**366**
CANC-25	Molecular Pathology	**372**
CANC-26	Epitranscriptomics of Cancer, Neurodegeneration and Rare Diseases	**378**
CANC-27	Biophysics of Metastasis and Anti-Tumor Immune Response Group	**386**
CANC-28	Mature Lymphoproliferative Neoplasms	**392**
CANC-29	Nanotechnology-Based Cancer Treatments	**406**
CANC-30	Dermato-Oncology: Genetics, Aging, and Immunology	**412**
CANC-31	Surgical Research	**420**
CARD	**Cardiovascular, Renal and Respiratory Area**	**428**
CARD-01	Cardiology	**436**
CARD-02	Thrombotic Pathology and Hemostasis	**458**
CARD-03	Translational Renal and Cardiovascular Research	**468**
CARD-04	Theranostics of Renal and Cardiovascular Diseases	**476**
CARD-05	Vascular Endothelial Pathophysiology	**484**
CARD-06	Vascular	**492**
CARD-07	Clinical Research in the Diagnosis and Treatment of Lung Neoplasms	**500**
CARD-08	Cardiovascular Pharmacology	**508**
CARD-09	Therapeutic Modulation of Blood Vessels in Pathology	**516**
CARD-10	Clinical Research in Respiratory Diseases	**524**
CARD-11	Cardiology Nursing Group	**532**

IBSAL

Instituto de Investigación Biomédica de Salamanca

Biomedical Research Institute of Salamanca
Paseo San Vicente 58-182, 37007 Salamanca, Spain

2. CONTEXT AND OBJECTIVES OF IBSAL

The Salamanca Biomedical Research Institute (IBSAL) is a **patient-centred**, **multidisciplinary and translational biomedical research centre**, with the Salamanca University Healthcare Complex (CAUSA) at its core. Its creation builds on a solid history of interdisciplinary and institutional collaborations, with the aim of improving the quality of research and, consequently, healthcare in Salamanca, as well as optimising human and material resources.

Being a Health Research Institute represents a **qualitative leap forward in the organisation and management of research**, with the aim of **maximising the quality of the research** carried out, the **impact** of its results and**, above all, the social return.**

IBSAL comprises research groups from **the Salamanca University Healthcare Complex (CAUSA),** which forms the core from which the institute originated, together with **primary care** groups **from the Salamanca Health Area**, groups from the **University of Salamanca (USAL)** and the **Spanish National Research Council (CSIC)**, as set out in the collaboration agreement signed on 21 March 2011 for its establishment.

In 2025, IBSAL comprises the following institutions and centres:

The Regional Health Authority of the Regional Ministry of Health, through:

- the Salamanca University Healthcare Complex (CAUSA).
- Primary Care Directorate of the Salamanca Health Area.

The University of Salamanca, through the services and research groups led by Academic Research Staff (PDI) at USAL who carry out their work in:

- The USAL departments that carry out research in the biomedical field.
- Castile and León Institute of Neurosciences (INCYL).
- Institute of Functional Biology and Genomics (IBFG).
- Cancer Research Centre (CIC).

The Spanish National Research Council (CSIC) through groups at the following centres:

- Institute of Functional Biology and Genomics (IBFG).
- Cancer Research Centre (CIC).

2.1. MISSION

IBSAL's mission is to strengthen translational research by fostering synergy between clinical and basic research groups, building on existing translational research models, as well as optimising resources through shared services and more efficient management structures.

2.2. VISION

IBSAL's vision is to become the leading health research institute for the Community of Castile and León, and to be a national and international benchmark in biomedical research. Furthermore, IBSAL shall contribute to the consolidation of the Salamanca Bio-health Campus and attract businesses to the campus.

2.3. STRATEGIC OBJECTIVES

IBSAL's strategic objectives, in line with its 2022–2026 Strategic Plan, are centred on research activities with the aim of:

1. Continue to drive scientific activity towards research excellence, specifically promoting collaborations between clinical and translational groups.

2. To establish an environment that facilitates the proper implementation of HR policy within the framework of the European HRS4R strategy through measures aimed at attracting and retaining talent, generational renewal, professional development and scientific competitiveness.

3. Increase the visibility of the platforms and their accessibility to IBSAL research staff, and consolidate the acquisition of resources from funding calls.

4. To strengthen the promotion and management of innovation and technology transfer activities at IBSAL.

5. To strengthen and consolidate relationships with stakeholders in the scientific and technological community, facilitating the transfer of research results.

6. To enhance IBSAL's scientific standing in society through the effective promotion of scientific activity and its impact.

2.4. LOCATION

IBSAL is situated on the Salamanca Bio-health Campus, a privileged and strategic location that makes the most of the proximity between clinical research and the healthcare activities carried out there. Its facilities are spread across the buildings of the Salamanca University Healthcare Complex, health centres in the Salamanca area, the faculties and schools of the University of Salamanca, the Castile and León Institute of Neurosciences, the Cancer Research Centre and the Institute of Functional Biology and Genomics. The Institute's administrative headquarters are located at the Salamanca University Healthcare Complex (CAUSA), in Outpatient Building 2 (Virgen de la Vega).

Campus
Bio-health
of Salamanca.




University Healthcare University



Consultations (Virgen de la Vega)





Faculties and schools of the University of Salamanca

Departmental Building



Faculties and schools at the University of Salamanca

Faculty of Pharmacy



Faculties and schools at the University of Salamanca

Faculty of Biology



Faculties and schools at the University of Salamanca

Faculty of Medicine



Centre for
Cancer Research
Centre




Institute of
Functional
Biology
and
Genomics



3. STRUCTURE AND ORGANISATION

The organisational structure of IBSAL is as follows:



3.1. GOVERNING BODIES

Governing Council

The Governing Council is the governing, representative and administrative body of IBSAL. All the centres that form part of the institute are represented on it.

Its key functions include approving IBSAL's strategic plan and the draft programme for IBSAL's research and training activities, together with the corresponding financial report.

Executive Committee


The Executive Committee is the Institute's executive governing body and aims to streamline the administration of IBSAL. It is responsible for implementing decisions of the Governing Council, reviewing programmes and annual reports, evaluating activities and proposing improvements.

3.2. IBSAL'S SCIENTIFIC DIRECTORATE

The Scientific Directorate is responsible for proposing and implementing IBSAL's scientific policy, as well as for planning and managing research infrastructure. It also coordinates the acquisition of resources, communicates the Institute's activities and prepares the annual research report. Furthermore, it oversees the quality of research, represents IBSAL in dealings with other institutions and may appoint or dismiss other key staff members.

The Institute's Scientific Management team comprises the following professionals:

Scientific Director
Dr Luis García Ortiz



Deputy Scientific Director
Dr Ángeles Almeida Parra

Deputy Scientific Director
Dr Jesús María Hernández Rivas

Scientific Secretary
Dr Candelas Pérez del Villar Moro

3.3. ADVISORY BODIES

External Scientific Committee

The External Scientific Committee is a body comprising professionals from outside IBSAL who are appointed by the Governing Council.

Its responsibilities include reviewing the annual reports and activity plans, including IBSAL's strategic plan, and assessing and considering the possible incorporation of new research groups into the institute.

Internal Scientific Committee

The Internal Scientific Committee is the body responsible for promoting and coordinating IBSAL's research activities.

Its functions include monitoring the quality of the institute's research, defining priority research areas, and ensuring their consistency and continuity.

3.4. THE SALAMANCA BIOMEDICAL RESEARCH FOUNDATION (FIBSAL)

The Salamanca Biomedical Research Foundation (FIBSAL) is the research management body of the Salamanca Biomedical Research Institute (IBSAL). Its founding objectives include, amongst others:

- To promote and facilitate the development and consolidation of biomedical research of excellence in Castile and León.
- To carry out its activities primarily within the territory of the Autonomous Community.
- To serve as a support platform for research staff and groups at the Salamanca Biomedical Research Institute (IBSAL), promoting innovation and the transfer of knowledge to society.

Its purpose is the financial and administrative management of research and innovation at IBSAL. Its remit is the management, dissemination and promotion of research and innovation programmes and projects in the biomedical and biotechnological fields, knowledge management and other activities related to research and innovation.

Management Directorate

The Management Department is currently headed by Ra-quel Carnicero Izquierdo, who is responsible for coordinating strategic planning, overseeing financial and project management, ensuring regulatory compliance, managing human resources and optimising internal operations. She also acts as a liaison with external organisations and oversees the institute's quality and accreditations.

Technical Management Unit

This is IBSAL's management body and is responsible for the Institute's financial, administrative and human resources management.

The IBSAL Technical Management Unit is located on the 10th floor of Outpatient Building 2 (Virgen de la Vega) at Paseo de San Vicente, 58-182. Its structure is shown on the following page.

3.5. COMMITTEES AND BOARDS

Innovation Commission

Coordinator: Jesús Francisco Bermejo Martín


The IBSAL Innovation Committee is an advisory and support body whose main objective is **to promote the transfer of scientific knowledge to society**, particularly by capitalising on research findings with potential for practical application.

In 2025, they held a total of 6 meetings.



Commission for Innovation

Structure of the Technical Management Unit Management



Equality Commission

Coordinator: Ángeles Almeida Parra

The IBSAL Equality Committee aims to integrate the principles of **gender equality** into the institute's scientific culture, promoting research that is more ethical, inclusive, open and aligned with the needs of society.

In 2025, the committee met once

Quality Committee

Coordinator: J. Ángel Maderuelo Fernández

The IBSAL Quality Committee is a body responsible for ensuring and promoting continuous quality improvement in all the institute's activities, particularly in relation to research, management and support.

In 2025, they held a total of four meetings.

Training Committee

Coordinator: Carlos Martínez Salgado

The IBSAL Training Committee is the body responsible for planning, coordinating and evaluating training activities aimed at the institute's research staff and other personnel, with the aim of promoting professional and scientific development within the field of biomedical research.

In 2025, they held a total of 2 meetings.

Citizens' Committee

Coordinator: Pilar Samaniego de Tiedra

The IBSAL Citizens' Committee is a participatory body whose aim is to bring biomedical research closer to society, promoting transparency, public engagement and the alignment of research with the real needs of the population.

In 2025, it met once.

IBSAL Research Integrity Committee

Coordinator: José Juan García Marín

The IBSAL Research Integrity Committee is the body responsible for ensuring ethical conduct in research, guaranteeing compliance with standards of scientific integrity and promoting a culture of responsibility, rigour and transparency amongst the institute's research staff.

It was established in 2025.

Single-member advisory bodies

Researcher Ombudsman: José Juan García Marín

The IBSAL Researcher Ombudsman is an independent figure whose main mission is to protect and promote the rights, wellbeing and integrity of research staff, acting as a mediator in disputes and ensuring a fair, ethical and respectful working environment.

Other external bodies supporting the institute's activities

Ethics Committee for Research Involving Medicines

Research Ethics Committee







3.6. RESEARCH AREAS AND GROUPS

IBSAL's thematic research areas, under which the Institute's research groups are grouped, are subdivided into vertical and horizontal areas.

At the head of each of these areas are the area coordinators: one with a clinical research background and the other with a background in basic research.

Vertical


- Cancer
- Neurosciences
- Cardiovascular, renal and respiratory
- Infectious, Inflammatory and Metabolic Diseases

Cross-cutting

- Gene and cell therapy and transplants
- Primary care, public health and pharmacology

At the helm of each of these areas are the area coordinators: one with a background in clinical research and the other in basic research.


RESEARCH GROUPS



NUMBER OF GROUPS PER AREA



NUMBER OF GROUPS BY TYPE



All the institute's scientific activity takes place within the research groups.

IBSAL's research staff is organised into **88** research **groups**, classified as established (C), emerging (E) or clinical associate (A) groups, in accordance with the criteria approved at the meeting of the IBSAL Governing Council on 27 February 2025. These criteria specify that:

A research group is a collective of researchers with a shared track record, as evidenced by a record of joint publications and access to research funding. The group must be defined by its research focus and not necessarily by its clinical or departmental affiliation.

Established groups

Those research groups that demonstrate, at least over the last 5 years:

1. Securing funding through competitive public, state or international calls for proposals, to support the development of their research areas and the recruitment of research staff.

2. Stable lines of research, developed through successive projects.

3. Collaborative scientific output of proven quality, alongside innovation activity expressed through the sustained development, over the same period, of initiatives for innovation and translation into the clinical setting (implementation of CPGs, innovation in healthcare processes) and the productive sector (patents, development of medical devices, etc.).

4. Proven capacity to train pre-doctoral research staff and technical support staff.

Emerging groups

Those groups that meet one of the following criteria:

1. A research group that has independently secured funding for its first project through competitive public calls for proposals at national level within the last three years.

2. A group with stable research activity which, in the last five years, has secured at least two research projects through competitive public calls for proposals at regional level, and has been listed as an author (as first, last or corresponding author) in publications of proven quality within its field of study.

Associated clinical groups

Groups of clinical professionals will be considered as such if they can demonstrate, over the last five years, a stable collaboration with another research group (whether established or emerging) at the IIS, carrying out activities such as recruiting participants, collecting data and/or analysing information in competitively funded research projects.

Groups carrying out research on individual projects with non-competitive funding will also be considered as such.

3.7. PLATFORMS AND INFRASTRUCTURE

Biostatistics

Co-ordinators: José Manuel Sánchez Santos and Francisco Javier Martín Vallejo

Collaborators: 14

Contract staff: 0

Number of services provided: 13

Proteomics

Coordinator: Manuel Fuentes García Collaborators: 4

Contract staff: 2

Number of services provided: 30

Biobanks (ISCIII Platform)

Coordinator: Andrés Celestino García Montero

Collaborators: 15

Staff employed: 5

Number of services provided: 148

Biomodels (ISCIII Platform) Coordinator:

Manuel Adolfo Sánchez Martín Collaborators: 0

Staff employed: 4

Number of services provided: 142

REDCap

Coordinator: Cristina Lugones Sánchez

Collaborators: 0

Staff employed: 0

Number of services provided: 11

Clinical Epidemiology and Methodology

Coordinator: Ricardo López Pérez

Collaborators: 0

Staff employed: 1

Number of services provided: 93

Bioinformatics

Coordinator: Carlos Prieto Sánchez

Collaborators: 4

Staff employed: 0

Number of services provided: 17

Clinical trials (ISCIII Platform)

Coordinator: Esperanza López Franco

Collaborators: 0

Staff employed: 1

Number of services provided: 1

Innovation and medical devices (I.T.SAL)

Coordinator: Jesús F Bermejo Martín Collaborators: 8

Staff employed: 1

Number of services provided: 44

Biomarkers

Coordinator: Jesús F Bermejo Martín Collaborators: 0

Staff employed: 3

Number of services provided: 1

Cardiac Imaging

Coordinator: Mª Candelas Pérez del Villar Moro

Collaborators: 13

Staff employed: 3

Number of services provided: 0

Viral Vector Production and Molecular Cloning (Vi-ralForge IBSAL)

Coordinator: Rubén Deogracias Pastor

Collaborators: 0

Staff employed: 0

Number of services provided: 0

3.8. RESEARCH STRUCTURES IN WHICH IBSAL PARTICIPATES

NETWORKS

Name	Reference	Researcher
Inflammatory Diseases	RD21/0002/0054	Ignacio Jesús Dávila González
RICORS2040	RD21/0005/0004	Carlos Martínez Salgado
RICORS-ICTUS	RD21/0006/0005	Ángeles Almeida Parra
Research Network on Chronic Conditions, Primary Care and Health Promotion (RICAPPS)	RD21/0016/0010	Luis García Ortiz
RICORS TERAV	RD21/0017/0006	Fermín Sánchez-Guijo Martín
Primary Care Addiction Research Network (RIAPAd)	RD24/0003/0017	Miguel Marcos Martín
RICORS2040-Renal	RD24/0004/0024	Carlos Martínez Salgado
Research Network on Chronic Conditions, Primary Care, and Health Prevention and Promotion (RICAPPS)	RD24/0005/0018	Luis García Ortiz
Inflammatory Diseases Network (REI)	RD24/0007/0032	Ignacio Jesús Dávila González
RICORS – STROKE	RD24/0009/0005	Ángeles Almeida Parra
TERAV+	RD24/0014/0034	Fermín Sánchez-Guijo Martín

CIBER

Name	Reference	Researcher
3. Frailty and Ageing. 3.1. Biological mechanisms of healthy ageing aimed at maintaining functional autonomy, and mechanisms leading to frailty and disability. (CICERFES)	CB16/10/00282	Juan Pedro Bolaños Hernández
4. Cardiovascular diseases. 4.1. Myocardial alterations and their consequences on the heart's functions and rhythm 4.1.10. Clinical research on the prevention and treatment of myocardial damage associated with ischaemia and chemotherapy. (CIBERCV)	CB16/11/00374	Pedro Luis Sánchez Fernández
5. Cancer. 5.6. Haematological tumours: innovations in diagnosis and precision therapy, and assessment of their usefulness in controlled clinical trials (clinical trials and standard practice) (CIBERONC)	CB16/12/00233	Ramón García Sanz
CIBER for Respiratory Diseases (CIBERES)	CB22/06/00035	Jesús Francisco Bermejo Martín
CIBER for Liver and Digestive Diseases (CIBEREHD)	CB06/04/0023	José Juan García Marín
CIBER for Cancer (CIBERONC)	CB16/12/00400	José Alberto Orfao De Matos Correia e Vale and Julia Almeida Parra
CIBER for Cancer (CIBERONC)	CB16/12/00317	Atanasio Pandiella Alonso

INTERNATIONAL NETWORKS

ECRIN: European Clinical Research Infrastructure Network.

COST: European Cooperation in Science and Technology.

EATRIS: European Infrastructure for Translational Medicine.

PLATFORMS

Name	Reference	Researcher
IBSAL's Independent Clinical Research Support Unit	PT23/00110	María Victoria Mateos Manteca
Biobank, Salamanca Institute of Biomedical Research (IBSAL)	PT23/00086	Andrés Celestino García Montero
Platform for the generation of genetically modified mouse biomodels	PT23/00123	Manuel Adolfo Sánchez Martín
Comprehensive platform for single-cell analysis and spatial transcriptomics	EQC2024-008765-P	Sandra Blanco Benavente






4. HUMAN RESOURCES


The total number of research staff, technical staff and management staff attached to IBSAL is **1,582**, comprising **66 per cent** women and **34 per cent** men. The average age is **43**.

They are distributed as follows:


NUMBER OF STAFF BY PROFESSIONAL CATEGORY



BREAKDOWN BY GENDER AND PROFESSIONAL CATEGORY




AVERAGE AGE BY PROFESSIONAL CATEGORY




4.1. RESEARCH STAFF

Number	Average age	Euraxess		Contracting organisation	
1410	43	R1	798	HUS	724
		R2	257	AP	119
		R3	202	USAL	449
		R4	153	CSIC	25
				IBSAL	93


Gender	Number	%	Average age	Euraxess		Employer	
Women	864	61	42	R1	533	HUS	447
				R2	161	AP	89
				R3	113	USAL	253
				R4	57	CSIC	13
						IBSAL	62
Men	546	39	45	R1	267	HUS	277
				R2	95	AP	30
				R3	88	USAL	196
				R4	96	CSIC	12
						IBSAL	31



AREA COORDINATORS




GROUP LEADERS



STUDENTS ENROLLED IN DOCTORAL PROGRAMMES

4.2. RESEARCH STAFF IN CHARGE OF PROJECTS




* These staff are included in the total number of research staff

4.3. TECHNICAL STAFF

Number	Average age	Employing organisation	
155	42	HUS	49
		AP	0
		USAL	32
		CSIC	2
		IBSAL	72

Gender	Number	%	Average age	Employer	contracting
Women	131	85	43	HUS	42
				AP	0
				USAL	29
				CSIC	1
				IBSAL	59
Men	24	15	41	HUS	7
				AP	0
				USAL	3
				CSIC	1
				IBSAL	13
TOTAL	155	100%	42		

4.4 MANAGEMENT STAFF



MANAGEMENT STAFF



5. TRAINING

SUMMARY FOR 2025

	TOTAL	HOURS	LEVEL OF SATISFACTION	ATTENDEES
IBSAL COURSES	13	141	9.14	159
PREDOC SEMINARS	20	22	7.20	375
IBSAL CONFERENCE	4	31	9.00	934
COLLABORATION ON OTHER COURSES	16	120	9.88	189
COLLABORATION IN OTHER CONFERENCES	10	61	9.23	438
COLLABORATION ON HUS COURSES	28	115	9.16	130

5.1 IBSAL TRAINING PROGRAMME

IBSAL Courses

REFERENCE	COURSE	DATE
IBSALC25001	Implementation of the UNE-EN ISO 15189 standard: Haematology Laboratories.	10 March 2025
IBSALC25002	Statistical Analysis of Clinical Data: Basic Techniques using SPSS (2025)	3 April 2025
IBSALC25003	A Sex-Gender Perspective in Biomedical Research	13 May 2025
IBSALC25004	Research data management	20 May 2025
IBSALC25005	Practical workshop on pharmacokinetic monitoring of biologics in inflammatory bowel disease	19 June 2025
IBSALC25006	Dissemination of scientific research findings. Doctoral theses. Scientific articles.	25 June 2025
IBSALC25007	Practical introduction to microscopic image analysis using Fiji/ImageJ	7 July 2025
IBSALC25008	Introduction to macro development with FIJI/ImageJ	14 July 2025
IBSALC25009	2nd Edition: Sex and Gender Perspectives in Biomedical Research	9 October 2025
IBSALC25012	Introduction to Bioinformatics for Biomedical Research	12 November 2025
IBSALC25013	Introduction to Proteomics and its Biomedical Applications	2 December 2025
IBSALC25014	Course on Good Clinical Practice (GCP) 2025	9 December 2025
IBSALC25015	Course on Molecular Genetics Techniques for Laboratory Technicians	15 December 2025

IBSAL Seminars

REFERENCE	SEMINAR	DATE
IBSALS250002	From the laboratory to the clinic. Molecular biology in chronic B-cell lymphoproliferative syndromes	21 January 2025
IBSALS250003	Early socio-communicative development in preterm babies during the first two years of life.	11 February 2025

REFERENCE	SEMINAR	DATE
IBSALS250004	"Acute kidney injury in patients receiving treatment with immune checkpoint inhibitors. A study of urinary biomarkers of tubulointerstitial nephritis and risk factors.	25/02/2025
IBSALS250005	Inhibition of αvβ3/αvβ5 integrins reduces tumour growth via vessel co-option and promotes a favourable microenvironment in experimental lung metastases.	11 March 2025
IBSALS250006	Proteomics in chronic, infectious and tumour-related conditions	25 March 2025
IBSALS250007	Dysregulation of p53 and apoptosis proteins in multiple myeloma	8 April 2025
IBSALS250008	Molecular mechanisms involved in nociception and the progression of osteoarthritic pain	13 May 2025
IBSALS250009	MDPI Open Science Insights Scientific Publishing Exchange at the University of Salamanca	27 May 2025
IBSALS250010	Study of the haematopoietic niche and inflammation in CAR-T treatment toxicity	27 May 2025
IBSALS250011	Cancer research and its application to artificial intelligence: experiences from Colombia	11 June 2025
IBSALS250012	Cell-specific transcriptomic profiling of cancer patients using single-cell and full-transcriptomics data based on advanced bioinformatics methods	17 June 2025
IBSALS250013	Clinical Epidemiology and Methodology Platform	24 June 2025
IBSALS250014	Call for applications for pre-doctoral grants under the IBSAL 2025 Grants Scheme	22 September 2025
IBSALS250015	NEXT-GENERATION CAR-NK PLATFORM: Gene editing for more effective immunotherapy in acute myeloid leukaemia	14 October 2025
IBSALS250016	The Potential for Repair: Astrocytic Lipid Metabolism Plays a Key Role in Brain Repair after Ischaemia	11 November 2025
IBSALS250017	Quarterly session: Presentation of platforms: IBSAL's Platform for Innovation, Translation and Transfer	25 November 2025
IBSALSHR250001	Research evaluation. COARA's progress	23 January 2025
IBSALSHR250002	Gender policies in research	6 February 2025
IBSALSHR250003	Implementation of HRS4R initiatives at IBSAL	20 February 2025
IBSALSHR250004	Knowledge transfer in the biomedical field	19 March 2025

IBSAL Conference

REFERENCE	CONFERENCE	DATE
IBSALJ25001	Presentation by the AES	10/02/2025
IBSALJ25002	4th IBSAL Scientific Conference	10 June 2025
IBSALJ25003	3rd ISCIII Platforms Conference	27 October 2025
IBSALJ25004	IBSAL Infoday: Horizon Europe. Health Cluster 1 and Open Forum with Researchers	28 May 2025

5.2 STAYS

Visits by IBSAL research staff to other national or international institutions.

Scope	Duration	Total
National	>2 months	9
International	>2 months	33
Subtotal > 2 months		**42**
National	< 2 months	2
International	< 2 months	5
Subtotal < 2 months		**7**
TOTAL		**49**


Visits by external research staff to IBSAL.

Scope	Duration	Total
domestic	>2 months	3
international	>2 months	20
Subtotal > 2 months		**23**
domestic	<2 months	2
international	<2 months	11
Subtotal < 2 months		**13**
TOTAL		**36**

5.3 THESES

An important indicator of the training activities for new researchers is the number of PhD students who defend their doctoral theses each year.

In 2025, IBSAL's PhD students defended a total of **74 theses**.







ECONOMIC DATA

6.1 REVENUE


TOTAL REVENUE



PUBLIC AND PRIVATE REVENUE




COMPETITIVE AND NON-COMPETITIVE INCOME




BREAKDOWN OF COMPETITIVE AND NON-COMPETITIVE INCOME

REVENUE FROM GRANTS AWARDED THROUGH COMPETITIVE PROCESSES, BY FUNDING AGENCY:




*This income is not included in the total, as the funds are not managed by IBSAL.

REVENUE BY NATURE (NON-COMPETITIVE)



6.2. INDIRECT COSTS ALLOCATED TO HR SUPPORT ACTIVITIES



6.3 BALANCE SHEET OF STATEMENT

NORMAL balance sheet as at 31 August 2025 Assets
2025

A) NON-CURRENT ASSETS	NOTES	1,393,646.58
I. Intangible fixed assets.	4	14,909.22
5. Computer software		14,909.22
6. Rights over assets transferred for use		
II. Historical Heritage Assets.		
III. Tangible fixed assets.	3	1,378,737.36
2. Technical installations and other tangible fixed assets		1,378,737.36
IV. Investment property.		
V. Long-term investments in group companies and associates.		
VI. Long-term financial investments.		
VII. Deferred tax assets.		
VIII. Non-current trade payables.		
1. Non-trade receivables from own operations	5.1.2	
B) CURRENT ASSETS		
Non-current assets held for sale		35,996,156.47
II. Stock.		
6. Advances from suppliers		149,602.22
III. Users and other debtors arising from the company's own operations.	5.1.2 and 6	149,602.22
IV. Trade debtors and other accounts receivable		3,655,735.96
1. Trade receivables from sales and services rendered	5.1.1	1,420,362.74
2. Sundry receivables (Institutes)		
3. Debtors and staff	1	
6. Other receivables from public authorities	9	2,235,373.22
IV. Short-term investments in group companies and associates.		
V. Short-term financial investments.		599,556.30
5. Other financial assets		599,556.30
VI. Short-term accruals.		13,218.46
VII. Cash and other cash equivalents.	5.3	28,072,396.42
1. Cash		28,072,396.42
TOTAL ASSETS (A + B)		37,389,803.05

NORMAL Balance Sheet as at 31 August 2025: Equity and Liabilities 2025

A) NET ASSETS	NOTES	7,231,219.18
A-1) Equity.		7,208,606.18
I. Founding endowment/Social fund		
1. Foundation endowment/Social fund.		
II. Reserves.		
2. Other reserves		
III. Surpluses from previous financial years.	8.1	6,542,899.53
1. Surplus		6,542,899.53
2. (Deficits from previous financial years)		
IV. Surplus for the financial year.	2	665,706.65
A-2) Adjustments for changes in value.		16,455.00
I. Available-for-sale financial assets		16,455.00
A-3) Grants, donations and bequests received.	12	6,158.00
I. Grants		6,158.00
II. Donations and bequests		
B) NON-CURRENT LIABILITIES		15,568,850.67
I. Long-term provisions.	11	653,681.28
II Long-term liabilities.		
III. Long-term liabilities to group entities and associates.		
IV. Deferred tax liabilities.		
V. Long-term accruals.		
VI. Non-current trade payables	5,210,169.39	14,915,169.39
1. Trade payables arising from the company's own operations		4,398,307.97
2. Accounts payable to research partners		10,516,861.42
C) CURRENT LIABILITIES		14,589,733.20
II. Short-term provisions	11	149,602.22
III. Short-term liabilities.	5.2.3	12,967,363.57
1. Short-term liabilities convertible into grants		12,967,363.58
2. Work centre accounts		-0.01
IV. Beneficiaries – Non-current trade creditors (short-term)	7	
1. Creditors arising from the company's own operations (CE C.P.)		
V. Trade creditors and other accounts payable.		732,981.68
1. Suppliers.		149,602.22
2. Sundry creditors.	5.2.3	235,537.01
3. Staff (outstanding remuneration)	5.2.3	0
6. Other debts to public authorities	9	225,975.31
7. Advance payments received for orders.	5.2.3	121,867.14
VI. Short-term accruals.		739,785.73
TOTAL EQUITY AND LIABILITIES (A + B + C)		37,389,803.05
VI. Short-term accruals.		850,785.73
TOTAL EQUITY AND LIABILITIES (A + B + C)		39,605,625.38

ABRIDGED profit and loss account as at 31 August 2025.

IECSCYL FOUNDATION Profit and Loss Account	NOTE	2025
A) Surplus for the financial year		665,706.65
1. Income from own activities.		4,932,892.16
a) Membership and affiliation fees.		
b) User contributions	10.5	5,160.40
c) Income from sponsors and donations	10.5	344,255.07
(d) Grants and bequests charged to the surplus for the financial year.	12	4,391,278.68
e) Donations	12	192,198.01
2. Sales and other income from ordinary activities		4,861,676.82
3. Expenditure on grants and other items.		-331,355.06
a) Financial grants.	10.1	-331,355.06
b) Non-monetary grants.		
c) Expenditure on partnerships and the governing body.		
d) Repayment of grants, donations and bequests.		
4. Change in stocks of finished goods and work in progress.		
5. Work carried out by the entity on its own assets.		
6. Purchases.	10.2	-1,617,537.63
7. Other operating income.		1,150.00
8. Staff costs.	10.3	-4,615,256.69
9. Other operating expenses.	10.4	-2,455,225.80
10. Depreciation of fixed assets.	3 – 4	-260,650.12
11. Grants, donations and capital bequests transferred to the surplus for the financial year.	12	
12. Excess provisions.		
13. Impairment and gains or losses on disposals of fixed assets.		
14. Other gains and losses	10.7	-9,174.31
A.1) OPERATING SURPLUS (1+2+3+4+5+6+7+8+9+10+11+12+13+14)		506,519.37
15. Financial income.		164,101.37
16. Financial expenses.		-608.39
17. Change in fair value of financial instruments.		
18. Exchange differences.		-114.30
19. Impairment and gains or losses on disposals of financial instruments.		
A.2) SURPLUS FROM FINANCIAL OPERATIONS (15+16+17+18)		163,378.68
A.3) SURPLUS BEFORE TAX (A.1+A.2)		669,898.05
20. Income tax.		-4,191.40
A.4) Change in equity recognised in the profit for the financial year (A.3+20)		665,706.65

NORMAL balance sheet at the end of the 2025 financial year

Assets 2025

A) NON-CURRENT ASSETS	NOTES	1,378,793.03
I. Intangible fixed assets.	8	11,158.04
5. Computer software		11,158.04
6. Rights over assets transferred for use		
II. Historical Heritage Assets.		
III. Tangible fixed assets.	5	1,367,634.99
2. Technical installations and other tangible fixed assets		1,367,634.99
IV. Investment property.		
V. Long-term investments in group companies and associates.		
VI. Long-term financial investments.		
5. Other financial assets		
VII. Deferred tax assets.		
VIII. Non-current trade payables.	10.1.2	
1. Non-trade receivables from own operations		
B) CURRENT ASSETS		38,226,832.35
Non-current assets held for sale		
II. Stock.		
III. Customers and other debtors arising from the company's own operations.	10.1.2 and 11	3,480,009.25
IV. Trade receivables and other receivables		3,150,880.11
1. Trade receivables from sales and the provision of services	10.1.1	942,365.69
2. Miscellaneous debtors (Institutes)		
3. Debtors and staff	10.1.1	
6. Other receivables from public authorities	16	2,208,514.42
IV. Short-term investments in group companies and associates.		
V. Short-term financial investments.		604,683.42
5. Other financial assets		604,683.42
VI. Short-term accruals.		27,744.61
VII. Cash and other cash equivalents.	10.3.d	30,963,514.96
1. Cash		30,963,514.96
TOTAL ASSETS (A + B)		39,605,625.38

NORMAL balance sheet at the end of the 2025 financial year Equity and Liabilities 2025

A) NET EQUITY	NOTES	7,494,087.71
A-1) Equity.		7,472,731.83
I. Founding endowment/Social fund	13.1	30,000.00
1. Founding endowment/Social fund.		30,000.00
II. Reserves.	13.2	
2. Other reserves		
III. Surpluses from previous financial years.	13.3	7,208,606.18
1. Surplus		7,208,606.18
2. (Deficits from previous financial years)		
IV. Surplus for the financial year.	3	234,125.65
A-2) Adjustments for changes in value.		16,455.00
I. Available-for-sale financial assets		16,455.00
A-3) Grants, donations and bequests received.	21	4,900.88
I. Grants		4,900.88
II. Donations and bequests		
B) NON-CURRENT LIABILITIES		14,536,069.75
I. Long-term provisions.	18	1,846,940.08
II Long-term liabilities.		
III. Long-term liabilities to group entities and associates.		
IV. Deferred tax liabilities.		
V. Long-term accruals.		
VI. Non-current trade payables	10,212,129.67	12,689,129.67
1. Trade payables arising from own operations		2,172,268.25
2. Research creditors – research fund		10,516,861.42
C) CURRENT LIABILITIES		17,575,467.92
I. Liabilities related to non-current assets held for sale		
I. Short-term provisions.		
II. Short-term debts.	10,222	16,087,131.33
1. Current liabilities convertible into grants		16,087,131.33
5. Work centre accounts		
III. Short-term payables to group entities and associations.		
IV. Beneficiaries – Non-current trade creditors (short-term)		
1. Creditors benefiting from the company's own operations (CE C.P.)		
V. Trade payables and other accounts payable.		637,550.86
1. Suppliers.		
2. Sundry creditors.	10.2.4	156,072.62
3. Staff (outstanding remuneration)	10.2.4	
6. Other debts to public authorities	16	352,010.06
7. Advances received on orders.	10.2.4	129,468.18
VI. Short-term accruals.		850,785.73
TOTAL EQUITY AND LIABILITIES (A + B + C)		39,605,625.38

ABRIDGED profit and loss account for the financial year 2025.

IECSCYL FOUNDATION Profit and Loss Account	NOTE	2025
A) Surplus for the financial year		234,125.65
1. Income from own activities.		3,701,361.76
a) Membership and affiliation fees.		
b) User contributions		-357.00
c) Income from promotional activities, sponsors and partnerships.	17.5	222,888.32
d) Grants, donations and bequests allocated to the surplus for the financial year.	21	3,411,761.58
e) Donations		67,068.86
2. Sales and other income from ordinary activities		1,788,611.04
3. Expenditure on grants and other items.		-116,974.47
a) Financial grants.	17.1	-116,974.47
b) Non-monetary grants.		
c) Expenditure on partnerships and the governing body.		
d) Repayment of grants, donations and bequests.		
4. Change in stocks of finished goods and work in progress.		
5. Work carried out by the entity on its own assets.		
6. Purchases.	17.2	-963,119.66
7. Other income from operations.		400.00
8. Staff costs.	17.3	-2,173,388.09
9. Other operating expenses.	17.4	-1,920,478.64
10. Depreciation of fixed assets.	5 – 8	-91,677.23
11. Grants, donations and capital bequests transferred to the surplus for the financial year.	21	1,257.12
12. Excess provisions.		
13. Impairment and gains or losses on disposals of fixed assets.		
14. Other gains and losses	17.7	684.13
A.1) OPERATING SURPLUS (1+2+3+4+5+6+7+8+9+10+11+12+13)		226,675.96
15. Financial income.		3,546.27
16. Financial expenses.		-850.96
17. Change in fair value of financial instruments.		5,127.12
18. Exchange rate differences.		-372.74
19. Impairment and gains/losses on disposals of financial instruments.		
A.2) SURPLUS FROM FINANCIAL OPERATIONS (15+16+17+18)		7,449.69
A.3) SURPLUS BEFORE TAX (A.1+A.2)		234,125.65
20. Income tax.		
A.4) Change in equity recognised in the profit for the financial year (A.3+18)		234,125.65


20x
PLAN
0X/0.65

7. RESEARCH ACTIVITIES

7.1. PROJECTS

COMPETITIVE PROJECTS

Nature	Managed by IBSAL	Not managed by IBSAL	Total Projects
European/international	26	26	52
National	81	43	124
Regional	47	30	77
Local	22	12	34
Total	176	111	287


NEW COMPETITIVE PROJECTS

Nature	Managed by IBSAL	Not managed by IBSAL	Total Projects
European/international	4	4	8
National	18	9	27
Regional	41	13	54
Local	6	7	13
Total	69	33	102


Number of new competitive research projects managed by IBSAL involving public participation: 22 / 69.

7.2. CLINICAL TRIALS

ACTIVE CLINICAL TRIALS



NEW CLINICAL TRIALS



*EECC: Clinical trials

*OES: Observational studies

7.3. HR VACANCIES

Vacancy	Active		New	
Call for applications	**Managed by IBSAL**	**Managed by other institutions**	**Managed by IBSAL**	**Managed by other institutions**
Juan Rodes	2	0	1	0
Miguel Servet	2	0	2	0
Sara Borrell	4	0	2	0
Rio Hortega	6	0	3	0
Ramón y Cajal	0	1	0	0
Intensification	8	0	8	0
Pre-doctoral	13	9	1	4
Mobility	8	0	8	0
Juan de la Cierva	1	1	0	0
Technical Support Staff	2	3	2	1
Postdoctoral	0	2	0	2
Other	2	3	1	1
TOTAL	67		36	

7.4. PUBLICATIONS

Type	With IBSAL affiliation	Not affiliated with IBSAL	Total	OA*
Articles	436 (68.34%)	202 (31.66%)	638	521 (81.66%)
Reviews	74 (71.15%)	30 (28.85%)	104	94 (90.38%)
TOTAL	510 (68.73%)	232 (31.27%)	742	615 (82.88%)


*OA: Open Access

Others (letters, letters to the editor, etc.)	29	13	42	25
Indexed clinical practice guidelines	8	3	11	9

PUBLICATIONS (ARTICLES, REVIEWS, INDEXED CLINICAL PRACTICE GUIDELINES)

Quartile	No.	%
D1*	234	31.54%
Q1	457	61.59%
Q2	141	19.00%
Q3	35	4.72%
Q4	6	0.81%
No quartile	103	13.88%
TOTAL	742	100%

*All these publications are included in Q1



[1] **Leadership indicator:** number of publications in which an IBSAL author is the corresponding author, first author or last author.

[2] **Excellence indicator:** number of IBSAL publications considered to be of excellence (included amongst the top 10 per cent of the most cited publications worldwide in their field of knowledge)

[3] **Inter-group collaboration:** number of collaborative publications by researchers belonging to different IBSAL groups

[4] **Cross-disciplinary collaboration:** number of collaborative publications by researchers from different disciplines within IBSAL

[5] **International collaboration:** number of publications involving international collaboration


LEICA DFC290 HD

8. INNOVATION

8.1. INDUSTRIAL AND INTELLECTUAL PROPERTY

Industrial property	Managed by IBSAL	Managed by other institutions
Patent	24	27
Utility model	7	2

Intellectual property	Managed by IBSAL	Managed by other institutions
Registration	1	28

Development of medical devices	Managed by IBSAL	Managed by other institutions
Registration	0	1

8.2. CLINICAL PRACTICE GUIDELINES AND INSTITUTIONAL DOCUMENTS

These are documents that set out a systematic set of recommendations, with the aim of assisting both clinical staff and patients in making decisions regarding the most appropriate interventions to resolve a problem in specific healthcare circumstances.

Only clinical practice guidelines (CPGs) published in peer-reviewed journals or developed on behalf of scientific societies or public authorities are considered as such. Conversely, CPGs produced by an institution for the internal use of its professionals that do not meet these criteria are not included.

In the case of institutional documents, account is taken of participation in recognised national or international bodies that draw up recommendations or position statements relating to health risks or public health. (Definition taken from the Glossary of the Technical Guide for the Evaluation of Health Research Institutes)

LIST OF CLINICAL PRACTICE GUIDELINES

Total: 29 documents.

- Agulló, C., Puig, N., Varo, N., Iglesias, M. Á., Mugueta, C., Pello, R., Paiva, B., Martínez-López, J., Castro, S., Cárdenas, M. C., García-Sanz, R., Pérez-Surribas, D., Flores-Montero, J., Ortiz-Espejo, M., de la Rubia, J., Cruz-Iglesias, E., Fontán, A., Isidoro-García, M., San-Miguel, J., & Mateos, M. V. (2025). Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Haematology and Haemotherapy. Part III: Clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry. Clinical Chemistry and Laboratory Medicine, 64(3), 586–599. https://doi.org/10.1515/cclm-2025-1056

- Aguilera, M. J. S., Gaspá, F. L., González-Flores, E., Mirón, M. L. L., Mozo, J. L. M., Del Carmen Riesco Martínez, M., Vidal-Tocino, R., Orduña, V. A., Martínez, E. A., & García, R. V. (2026). SEOM-GEMCAD-TTD clinical guidelines for localised rectal cancer (2025). Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 28(2), 451–462. https://doi.org/10.1007/s12094-025-04140-4

- Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutiérrez, N. C., Paiva, B., Neri, P., Weisel, K., Maura, F., Walker, B. A., Bus-toros, M., Stewart, A. K., Usmani, S. Z., Hillengass, J., Chng, W. J., Keats, J. J., … Munshi, N. C. (2025). International Myeloma Society/International Myeloma Working Group Consensus

Recommendations on the Definition of High-Risk Multiple Myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 43(24), 2739–2751. https://doi.org/10.1200/JCO-24-01893

- Cabrera Gómez, J., Navarro Matías, E., Ginel Mendoza, L., Cano Espín, A., Morán Bayón, Á., Martín Sánchez, V., & Serrano-Cumplido, A. (2025). Consensus document on COVID-19 from the Spanish Society of Primary Care Physicians (SEMERGEN). Current situation. SEMERGEN's Position in 2025 [Consensus Document on COVID-19 from the Spanish Society of Primary Care Physicians (SEMERGEN). Current Situation. SEMERGEN's Position in 2025]. Semergen, 51(5), 102516. https://doi.org/10.1016/j.semerg.2025.102516

- Genetic Catalogue. (n.d.). Common catalogue of genetic and genomic tests of the Spanish National Health System (SNS). https://cgen.sanidad.gob.es/ cgen_fe/#/

- Department of Health of the Regional Government of Castile and León. (2025). Breastfeeding Guide: The Natural Way. https://www. saludcastillayleon.es/es/salud-mujer/lactancia-materna. ficheros/2982426-Gui%C2%BFa%20Lactancia%20ed%20 2025.pdf

- 3 March (n.d.). Clinical protocol for the use of axicab-tagén ciloleucel in the treatment of adult patients with refractory or relapsed follicular lymphoma following three or more lines of systemic treatment within the National Health Service. Gob.es. Retrieved 4 May 2026, from https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/docs/04032025_Axicabtagen_ciloleucel_4_linea_LF.pdf

- 3 March. (n.d.-b). Clinical protocol for the use of brexucabtagene autoleucel in the treatment of patients with refractory or relapsed mantle cell lymphoma following two or more lines of systemic treatment within the National Health System. Gob.es. Retrieved 4 May 2026, from https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/docs/04032025_Brexucabtagen_autoleucel_linfoma_celulas_manto.pdf

- of Health, Directorate-General for Public Health and the Directorate-General for Social Services and General Health (undated). PROCESS FOR THE PREVENTION AND MANAGEMENT OF BEHAVIOURAL ISSUES
SUICIDE. Saludcastillayleon.es. Retrieved 4 May 2026, from https://www.saludcastillayleon.es/profesionales/es/care-processes/care-processes-regional-health-management/prevention-and-management-of-suicidal-behaviour. files/1110258-PROCESS%20FOR%20THE%20PREVENTION%20AND%20MANAGEMENT%20OF%20SUICIDAL%20BEHAVIOUR.pdf

- Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M. V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., Schjesvold, F., Gay, F., Manier, S., Weisel, K. C., Kaiser, M., van de Donk, N. W. C. J., Zamagni, E., Rodríguez-Otero, P., Perrot, A., Driessen, C., … Sonneveld, P. (2025). EHA-EMN Evidence-Based Guidelines for the diagnosis, treatment and follow-up of patients with multiple myeloma. *Nature Reviews: Clinical Oncology*, 22(9), 680–700. https://doi.org/10.1038/s41571-025-01041-x

- 2nd ed. (n.d.). Spanish Myeloma Group. Fundacionpethema.es. Retrieved 4 May 2026, from https://www.fundacionpethema.es/sites/default/files/2025-12/GUIA_PETHEMA_MM_2025.pdf

- García-García, R., Gimeno Peribáñez, M. A., Albi Rodríguez, M. S., Almonacid Sánchez, C., Alsina Restoy, X., Aguirre-Franco, C. E., Balañá Corberó, A., Chiner, E., Díaz López, M., Fernández Álvarez, R., Gaboli, M., García-Río, F., Godoy Mayoral, R., González Troiteiro, S., Hernández Mezquita, M. A., Martínez Llorens, J. M., Marcos, M. C., Martín, C., Solanes, I., Ortega Ruiz, F., … Vigil Giménez, L. (2026). Recommendations for Performing Spirometry. Archivos de bronconeumologia, S0300-2896(26)00012-8. Advance online publication. https://doi.org/10.1016/j.arbres.2025.12.016

- Castile and León Monoclonal Gammopathy Study Group. (2024). Haematology guidelines for the management of patients with multiple myeloma in Castile and León (version 5.2). Castile and León Society of Haematology and Haemotherapy.
https://www.sclhh.org/docs/pdf/consenso/guia%20mieloma%202024_version%20digital.pdf

- Spanish Group on Philadelphia-Negative Myeloproliferative Disorders (GEMFIN), & Spanish Society of Haematology and Haemotherapy (SEHH). (2025). Manual of recommendations for Philadelphia-negative chronic myeloproliferative neoplasms. https://manual-gemfin2025.gemfin.org/wp-content/uploads/2025/05/ManualGEMFIN2025.pdf

- Spanish Group on Lymphomas and Autologous Bone Marrow Transplantation (GELTAMO). (2025). Guidelines on the management of bispecific antibodies in B-cell non-Hodgkin's lymphomas. https://www. geltamo.com/descargas/solicitud-descarga/296-guia-anti-cuerpos-biespecificos-pdf-1/file

- Spanish Lymphoma and Autologous Bone Marrow Transplantation Group (GELTAMO). (2025). Guidelines for the diagnosis, treatment and follow-up of Waldenström's lymphoplasmacytic lymphoma/macroglobulinaemia and related conditions. https://www.geltamo.com/doclink/guia-linfoma-linfoplas-mocitico-y-mw-geltamo-pdf/eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiJndWlhLWxpbmZvbWEtbGluZm9wbGFzbW9jaXRpY28teS1tdy1nZWx0YW1vLXBk ZiIsImlhdCI6MTc2NTgwMTM1NCwiZXhwIjoxNzY1ODg3NzU0fQ.UxA8yZM51ZZqITu2rktlijvnC8OjUlo2o-xbL47aErg

- Ministry of Health. (2019). Pharmacoclinical protocol for the use of tisagenlecleucel and axicabtagene ciloleucel in diffuse large B-cell lymphoma within the National Health Service. https://www.sanidad.gob.es/areas/farmacia/infoMedicamentos/terapiasAvanzadas/docs/11042025_Protocolo_farmacoclinico_tisagenlecleucel_axicel_LBDCG.pdf

- Ministry of Health. (2025). Results of the study on the implementation of safe practices in the use of high-risk medicines in Spanish hospitals. https://seguridaddelpaciente.sanidad.gob.es/practicasSeguras/usoSeguroMedicamentos/docs/RESULTADOS_ESTUDIO_MAR.pdf

- Montes, A. F., Alonso, V., Aguilar, E. A., Élez, E., Alfonso, P. G., Castro, C. G., Maurel, J., García, R. V., Tocino, R. V., & Urtasun, J. A. (2025). 2025 Updated version v1.0 SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022). Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(4), 1845–1850. https://doi.org/10.1007/s12094-025-03860-x

- Muñoz Couselo, E., Cañueto, J., Jerviz Guía, V., López López, A. M., Bermejo Segú, J. O., García Castaño, A., Puig Sardá, S., Sanmartín Jiménez, O., Soria Rivas, A., Gratal, P., Pardo, M. T., Rogado, Á., & Berrocal Jaime, A. (2025). Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(7), 3058–3072. https://doi.org/10.1007/s12094-024-03826-5

- Musto, P., Engelhardt, M., van de Donk, N. W. C. J., Gay, F., Terpos, E., Einsele, H., Fernández de Larrea, C., Sgherza, N., Bolli, N., Katodritou, E., Gentile, M., Royer, B., Derudas, D., Jelinek, T., Zamagni, E., Rosiñol, L., Paiva, B., Caers, J., Kaiser, M., Beksac, M., … Sonneveld, P. (2025). European Myeloma Network Group review and consensus statement on primary plasma cell leukaemia. Annals of Oncology: official journal of the European Society for Medical Oncology, 36(4), 361–374. https://doi.org/10.1016/j.annonc.2025.01.022

- Otero, M. J., Marrodan, B. R., Santos, N. P., Pinto, E. V., Rodríguez, S. M., Peinado, R. P., Fernández-Llamazares, C. M., Rodríguez, A. M., & on behalf of the Spanish Association of Paediatrics, the Spanish Society of Hospital Pharmacy and the Autonomous Communities (2025). Recommendations for the safe use of high-risk medicines in paediatrics. Anales de Pediatría, 103(1), 503815. https://doi.org/10.1016/j.anpede.2025.503815

- Ramírez, S. P., Fidalgo, A. P., Ginesta, M. P. B., De Juan Ferré, A., Madrid, L. F., Martínez, A. G., Montosa, F. G., Madariaga, A., Gómez, T. M., & Gil-Martin, M. (2025). SEOM-GEICO clinical guidelines on endometrial cancer (2025). Clinical & Translational Oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(12), 4368–4380. https://doi.org/10.1007/s12094-025-04046-1

- Salinas, P., Cid Álvarez, A. B., Jorge Pérez, P., Vázquez-Álvarez, M. E., Jurado-Román, A., Juárez, M., Corbí-Pascual, M., Velázquez Martín, M., Jiménez-Mazuecos, J., Rosillo Rodríguez, S. O., Ruiz Quevedo, V., Lázaro, M., Viana-Tejedor, A., Martín Moreiras, J., & Martín-Asenjo, R. (2025). Catheter-directed interventions in acute pulmonary embolism. Position statement of the SEC-Interventional Cardiology Association/SEC-Ischaemic Heart Disease and Acute Cardiovascular Care Association/SEC-Working Group on Pulmonary Hypertension. Revista española de cardiología (English ed.), 78(3), 239–251. https://doi.org/10.1016/j.rec.2024.09.011

- Spanish Society of Haematology and Haemotherapy. (n.d.). Manual for the diagnosis and clinical management of germline predisposition to haematological neoplasms. https://sehh.es/publicaciones/manuales-publicaciones/126044-manual-for-the-diagnosis-and-clinical-management-of-germinal-predisposition-to-haematological-neoplasms

- Spanish Society for Thrombosis and Haemostasis. (n.d.). Guidelines for the diagnosis and treatment of congenital platelet disorders. https://www.seth.es/files-seth/publicaciones/Guia-de-trastornos-plaquetarios-congenitos.pdf

- Terpos, E., Trudel, S., Mateos, M. V., Alejandre, N., Colby, K., Dimopoulos, M. A., Esposti, S. D., Farooq, A. V., Gavriatopoulou, M., Gay, F., Hungria, V., Kortüm, K. M., Leleu, X., Lonial, S., Quach, H., Qiu, L., Ramasamy, K., Suzuki, K., Weisel, K. C., & Richardson, P. (2025). Practical Guidance on the Clinical Management of Belantamab Mafodotin-Associated Ocular Events. American Journal of Haematology, 100(10), 1839–1850. https://doi.org/10.1002/ajh.70015

- van de Donk, N. W. C. J., Moreau, P., San-Miguel, J. F., Mateos, M. V., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., Delforge, M., Beksac, M., Spencer, A., Schjesvold, F., Driessen, C., Kaiser, M., Perrot, A., Wäsch, R., Korst, C. L., Broijl, A., … EMN Guidelines Committee (2025). Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. The Lancet. Haematology, 12(8), e635–e649. https://doi.org/10.1016/S2352-3026(25)00117-6

- Velázquez Martín, M., Lojo Lendoiro, S., Soto Flores, N., Jiménez Gómez, E., Abadal Villayandre, J. M., Datino, T., Navia Álvarez, P., González Díaz, E. M., Bargalló Alabart, N., Bastan-te Valiente, T., Arzamendi Aizpurua, D., Martín Moreiras, J., & Cid Álvarez, B. (2025). Occupational exposure to ionising radiation in pregnant staff. Consensus document of ACI-SEC/ARC-SEC/SERVEI/SENR/SERAM/GeNI. REC, Interventional Cardiology, 7(4), 246–254. https://doi.org/10.24875/RECICE.M25000522


Calendario fotos
Contacto | Nucle
IBSAL
Proyectos - Grup
ES EN
la Investigación
Plataformas
Sociedad
Formación
Convocatorias
Contacto
11:12
14/10/2024
IBSAL
Instituto de Investigación
Biomédica de Salamanca


9. COMMUNICATION AND DISSEMINATION

9.1. IBSAL PRESS RELEASES

Date	News link
3 February 2025	An IBSAL study has identified a worrying increase in the risk of suicide among children and adolescents in the wake of the pandemic
18 March 2025	A study by IBSAL and USAL opens up new therapeutic avenues to improve the treatment of in women via serotonin receptors
27 March 2025	Ambitious national project to implement a preclinical model of personalised medicine for the early detection of dementia
2 April 2025	Pioneering trial to treat patients with relapsed multiple myeloma using a new academic CAR-T therapy
5 May 2025	The Mediterranean diet reduces cardiovascular risk in patients with long COVID
27 May 2025	National mega-project to improve the management of myelodysplastic syndromes through the incorporation of artificial intelligence and patient experience
10 June 2025	IBSAL reaches 632 scientific publications and adds 114 new competitive projects and 107 clinical studies clinical studies in 2024
12 November 2025	IBSAL is driving forward 12 cutting-edge projects in personalised medicine, cancer, chronic diseases and neurosciences with support from the ISCIII
2 December 2025	The IBSAL Grants Scheme allocates 230,000 euros across seven calls for proposals to boost the work of its researchers
18 December 2025 2025	IBSAL strengthens its research leadership with 16 projects funded under the ISCIII's Strategic Health Initiative

Number of press mentions: 211.

9.2 SOCIAL MEDIA



IBSAL has seen an increase in the number of followers across all social media platforms where it has an active account. The greatest growth has been on LinkedIn, with an increase of 933 followers, representing a growth rate of 17.93 per cent.

These are the posts with the greatest impact on each social media platform:



Facebook post



Post on Instagram



Post on LinkedIn



Post on X

9.3. NOTABLE ACTIVITIES OF THE IBSAL

4th IBSAL SCIENTIFIC CONFERENCE

IBSAL organised the 4th IBSAL Scientific Conference on 10 June 2025 at the Castilla y León Conference and Exhibition Centre.

This is an annual event that brings together 300 researchers from the institute to share their work, learn about that of others and explore potential synergies with other groups at IBSAL.

The first part of the conference was dedicated to the pre-doctoral community, featuring oral presentations of eight research projects and poster presentations of a further forty, all selected from the 73 submitted by the institutes' trainee staff.

The second part centred on the presentation of the institute's scientific report for the previous year, a presentation of three of the most prominent projects at national level coordinated by IBSAL, a round-table discussion on the national science strategy and research evaluation, and a presentation of the institute's research support platforms.



4th IBSAL
IBSAL Scientific
Conference

3rd CONFERENCE OF THE ISCIII PLATFORMS SUPPORTING R&D&I IN BIOMEDICINE AND HEALTH SCIENCES

IBSAL co-organised, together with the three platforms of the Carlos III Health Institute (ISCIII) —Biomodels and Biobanks, ITEMAS, and SCReN— the third edition of the ISCIII Platforms Conference on Support for R&D&I in Biomedicine and Health Sciences, held on 27, 28 and 29 October 2025 at the Castilla y León Conference and Exhibition Centre.

This annual event, held on this occasion in Salamanca, brought together more than 500 professionals involved in providing research support services.

The three-day event featured national and international presentations in these fields, panel discussions, poster sessions and parallel activities organised by each of the three ISCIII platforms.



3rd Conference on the ISCIII Platforms

EUROPEAN RESEARCHERS' NIGHT IN SALAMANCA

European Researchers' Night is a science communication project promoted by the European Commission as part of the Marie Sklodowska-Curie Actions under the Horizon Europe programme, which has been taking place simultaneously in almost 400 European cities since 2005.

In Salamanca, it is organised by the University of Salamanca's Scientific Culture and Innovation Unit, in collaboration with the ZOES Association. It takes place in the Plaza del Barrio del Oeste, featuring a wide range of street activities for people of all ages, with the participation of numerous researchers, as well as student associations and businesses.

As it does every year, IBSAL was present with a variety of science workshops for all ages: observing cells under a microscope, learning how to use a pipette, and making a lava lamp, slime and pufferfish using bicarbonate of soda and vinegar.



European Night of Researchers in Salamanca



10. RESPONSIBLE RESEARCH AND INNOVATION (RRI)

10.1. PUBLIC ENGAGEMENT ACTIVITIES

IBSAL's research groups are actively involved in initiatives to engage with society through a wide range of activities. The aim is to strengthen the link between biomedical research and society, promoting an understanding of scientific knowledge and its impact on health and everyday life, and fostering an ongoing dialogue between researchers and the public.

The table below shows the number of activities carried out by IBSAL research staff in 2025, broken down into the following categories:

- Public outreach talks: 66
- Outreach via digital media: 21
- Round-table discussions: 11
- Presentations: 26
- Workshop or course: 11
- Guided tour: 4

10.2. ACTIVITIES WITH CITIZENS' ASSOCIATIONS

CAFÉ CON-CIENCIA

The "Café Con-ciencia" activity is a science outreach initiative developed in collaboration with AFIBROSAL. Using a participatory format inspired by the World Café model, three themed talks were organised and delivered by research staff, followed by informal discussions in a café where attendees and professionals were able to exchange ideas in a relaxed atmosphere. The sessions addressed issues such as autoimmune diseases, new treatments and brain plasticity, fostering understanding and shared learning.



Café
Con- science

DIVERSE AND RESPONSIBLE HEALTH

The 'Diverse and Responsible Health' programme is a science communication initiative developed in collaboration with the Igualles association in Salamanca. Using a relaxed and informal format, four meetings were organised in a bar, where researchers, representatives of the association and attendees engaged in open discussions on key health issues. The sessions addressed issues such as sexually transmitted infections, the phenomenon of ChemSex, healthy lifestyles and mental health, always from an inclusive perspective and based on scientific evidence.



Diverse and Responsible Health

RESEARCH AND INNOVATION IN ACQUIRED BRAIN INJURY. TRANSFER OF RESULTS TO SALAMANCA SOCIETY

The initiative "Research and innovation in acquired brain injury. Transferring findings to the Salamanca community", carried out in collaboration with ASDACE, aimed to bring IBSAL's scientific knowledge on acquired brain injury to patients, family members, carers and the general public. To this end, four talks were organised at a municipal centre run by the city council, addressing various evidence-based approaches to rehabilitation and treatment. Topics included the use of neuroplasticity, the therapeutic application of music and movement, functional communication and the importance of individualised neuropsychological intervention.



Research and innovation in acquired brain injury

MIRADAS EN ACCIÓN

The ‘Miradas en Acción’ event, organised in collaboration with the Retina Salamanca Association, was a day of public science outreach focused on low vision, with the aim of bringing IBSAL’s expertise to the public and raising social awareness. Through presentations and a round-table discussion, topics such as research into the neurobiology of vision, clinical practice, the role of voluntary organisations and assistive technology were addressed.



Miradas in Action

10.3. EQUALITY IN SCIENCE

IBSAL collaborates with STEM Talent Girl, an innovative, high-impact educational project that aims to attract, develop and nurture scientific and technological talent amongst girls and young women in secondary school, sixth form, vocational training and university.

A group of students in their final years of secondary education visited the Faculty of Medicine at the University of Salamanca to find out first-hand what IBSAL is all about. They attended a motivational talk on academic studies and a career in research, as well as a suturing workshop using anatomical models.



Equality in science



11.PLAN FOR GRANTS 2025

The grants scheme launched in 2025 is designed to promote research in various areas, ranging from training to the dissemination of results. In total, it includes several lines of support tailored to the needs of research staff. For example, 15 grants have been made available for publishing open-access articles, with the aim of making research more visible and ensuring that anyone can access it free of charge.

There are also 20 grants aimed at pre-doctoral research staff to enable them to attend conferences, present their work and continue their professional development within the scientific community. In addition, six grants have been announced for placements at prestigious research centres, enabling them to learn, improve and collaborate with other professionals.

Furthermore, there are five grants for healthcare staff who also carry out research, so that they can reduce their clinical workload and devote more time to research. In addition, there are six grants for outreach projects, which aim to bring science closer to society through public engagement activities.

The most important part of the plan consists of the 18 grants for research projects, as these directly fund studies in various fields. In addition, there are two specific grants focused on mental health, which is an increasingly relevant issue.

Overall, all these grants aim to support research from various angles: helping those just starting out, facilitating training, fostering collaboration and ensuring that the results reach the wider public.

The grants awarded have therefore been distributed as follows:

2025 GRANT SCHEME	CALLS FOR APPLICATIONS			APPLIED FOR	AWARDED	
Type of grant	No.	Cost per unit	Total	No.	No.	Total
Publication of scientific articles in Open Access	15	€2,000	€30,000	11	8	€16,000
Participation in conferences by pre-doctoral research staff	20	€500	€10,000	19	17	€8,500
Research stays of scientific excellence	6	€3,000 / €5,000	€24,000	9	8	€32,500
Stepping up research activity amongst healthcare staff	5	€15,000 / €8,500	€62,000	6	4	€53,500
Projects to disseminate IBSAL's research to the public	6	€2,000 / €1,000	€9,000	14	7	€9,000
Research projects	18	€2,500 / €5,000 / €10,000	€75,000	36	18	€70,000
Grants for research areas			€20,000			
TOTAL	**72**		**€230,000**	**96**	**63**	**€189,500**